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First, there can be selection of more controls per case, which can improve the statistical power to estimate the association. This is one of the advantages of a population-based study which this study could also have taken advantage of. Second, it is vital to realize that Toxocara canis serology itself has a sensitivity of 78% and a specificity of 92% by enzyme-linked immunosorbent assay. The cross-reactions with other nematode infections (e.g., Ascaris lumbricoides, Stronglyloides) reduces its specificity further, particularly in tropical areas. [3] The association or the lack of it, does not really take us further, into Toxocara species and the occurrence of epilepsy. The sublime evidence still remains the lesion on imaging, which is putatively one of the parasites causing focal epilepsy. Studies looking at other parasites serology [4] [5] [6] are also fraught with the same limitation. The authors have indeed mentioned this as one of the limitations of their study. Third, the presence of asymptomatic calcified lesions in community dwellers in endemic areas and its association with parasitic serological studies will provide further insight into the etiopathogenesis of epilepsy. The community-based studies provide a high prevalence of asymptomatic calcified lesions (15.1%). [7] Thus, this study also provided an opportunity to image the cases and control population, to detect asymptomatic people (with positive or negative serology). This would have of course, entailed additional resources and budget, which becomes the challenge in conducting such studies. Last, and most importantly, the application of serology into clinical practice does not presently look tenable in patients with epilepsy, given that imaging provides better information and does not change management.
Nevertheless, conduct of such studies is vital for generating evidence regarding prevalence of infection as a preventable cause of epilepsy. This would drive the authorities for establishing prevention programs at population level. The authors need to be congratulated to have put efforts to provide this information.
This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. {Boehringer Ingelheim}] and was taking it regularly. On examination, he was conscious and had a or food interactions. Nevertheless, their anticoagulant effects can be tested by the diluted thrombin time (dTT), thrombin time (TT), or ecarin clotting time. Although the activated partial thromboplastin time (aPTT) can be used, it has a weaker correlation with Dabigatran levels or its anticoagulant effects. These tests were not feasible in our patient due to the lack of time and logistical constraints.
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Idarucizumab was designed as a specific reversal agent for patients treated with Dabigatran who developed life threatening or uncontrolled bleeding or required emergency surgery. It is a humanized monoclonal antibody fragment (Fab) that rapidly reverses the anticoagulant effect of Dabigatran and normalizes dTT and/or ECT in 88-98% of patients within minutes of idarucizumab infusion. This Fab has 300 times the affinity for Dabigatran than the NOAC has for thrombin. Additionally, the Fab-Dabigatran complex is a very stable complex that potently reverses the anticoagulant effect of Dabigatran by almost 100% in 4 h. [2] Thrombolytic treatment with IV recombinant tissue plasminogen activator (rtPA) was initially contraindicated in patients taking a NOAC. However, as the use of Dabigatran has increased exponentially, the contrarian situation necessitating its reversal in patients with an AIS, requiring iv rtPA has also correspondingly increased. There is now, data that Idarucizumab can be used safely to reverse Dabigatran effect before rtPA administration in AIS. [3] To our knowledge, this is the first reported case from India, of Dabigatran reversal with Idarucizumab in AIS followed by iv rtPA administration, although there is a report of Apixaban reversal. [4] Our report adds to the safety profile of Dabigatran reversal in this situation. Although Idarucizumab is expensive (approximately Rs 77,000/-for 5 g), it was provided gratuitously and promptly from the local distributor as the patient was taking the innovator product and had registered online via their "Pradaxa care and support Program." A patient who was instead, taking a biosimilar of Dabigatran would have to pay the "plena pretium" or full price. Hence, all clinicians should be aware of this therapeutic option in patients taking Dabigatran and prominent motor aphasia without buccofacial apraxia or dysphagia. He also had a mild right hemiparesis. A CT angiogram showed left M3 branch occlusion with essentially normal brain parenchyma. As he was not a candidate for mechanical thrombectomy and he was close to the end of the rtPA time window, he was administered Idarucizumab 5 g IV [Praxbind TM {Boehringer Ingelheim}] as two consecutive bolus infusions of 2.5 g each, over 10 min at 260 min from the time of onset. At the end of the infusion (270 min), rtPA 90 mg was initiated (9 mg bolus + 81 mg infusion over 1 h for a body weight of 110 kg). The infusion was completed uneventfully and an MRI brain after 24 h showed a left frontal opercular infarction without hemorrhagic transformation [ Figure 1] . At 24 h, he was commenced on low molecular weight heparin followed by Warfarin, after a rheumatology opinion. A repeat CT brain on day 5 showed no further changes. He made a steady recovery and was discharged on day 6 with minimal word finding difficulty.
Dabigatran etexilate is a non-vitamin K antagonist oral anticoagulant agent (NOAC) or direct oral anticoagulant. It is indicated to reduce systemic embolic events in patients with nonvalvular atrial fibrillation as well as in venous thromboembolism. [1] Dabigatran is a competitive reversible nonpeptide antagonist of thrombin (an enzyme that converts fibrinogen to fibrin). The newly formed cross-linked fibrin monomers activate factor XIII and accelerate further thrombin production via the activation of factors V and VIII with a procoagulant effect. Conversely, thrombin also has an anticoagulant effect in the coagulation cascade by activating platelets and protein C. Most of the actions of thrombin are inhibited by Dabigatran etexilate. It is a fast acting agent with an onset of action of 30 minutes and has a duration of anticoagulation of 24-36 h. The NOACs [Dabigatran (a direct thrombin inhibitor) or Apixaban, Rivaroxaban, Edoxaban (Factor Xa inhibitors)] offer noninferior efficacy and a good safety profile compared to the conventional vitamin K antagonists (VKA) such as Warfarin or Acenocoumarol. Their greatest advantages are that they do not need regular laboratory monitoring of their anticoagulant effect (different from the VKAs), dose adjustment is simpler, and they have fewer drug specifically the "gratuitous" offer of Idaricizumab on those taking the innovator product.
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The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed. Dengue fever is the second most common mosquito-borne disease affecting humans after malaria. Recently, virological characteristics of dengue viruses have been changing, resulting in widespread neurological complications which were found in 0.5%-21% of dengue cases. The central nervous system (CNS) complications comprise 95% of neurological complications, of which cranial neuritis is reported rarely in a few case reports. Few case reports are available regarding dengue-associated neuritis, such as brachial neuritis, long thoracic nerve palsy, phrenic, oculomotor, abducens, and peripheral facial palsy. We are describing a rare association of dengue fever causing facial palsy in a 65-year-old female.
Dengue made its debut as early as 1780 when Benjamin Rush described the condition as "break-bone fever." [1] It is the second most common mosquito-borne disease affecting humans after malaria. [2] Worldwide, nearly 2.5 billion people continue to live at the risk of contracting the infection, whereas 50 million cases and 20,000 deaths are estimated to occur in 100 endemic countries. [1] Estimates suggest 500,000 cases of dengue hemorrhagic fever occur in the Asian countries. [3] The clinical presentation of dengue has a wide spectrum, ranging from mild clinical febrile illness to severe life-threatening conditions such as dengue hemorrhagic fever and dengue shock syndrome. Recently, virological characteristics of dengue viruses have been changing, resulting in widespread neurological complications. [4] It is caused by arboviruses which belong to the Flaviviridae family. Dengue virus one to four are the known serotypes of the virus of which two and three serotypes are mostly associated with neurological manifestations. [1] The association of dengue infection and neurological abnormalities was first described by Sanguansermsri et al. in 1976 , in a patient presenting with encephalopathy. [5] Recently, virological characteristics of dengue viruses have been changing, resulting in widespread neurological complications, but their precise incidence rates remain undefined. Among these manifestations, encephalitis and encephalopathy are the most common neurological presentations. [6] We report a rare case of a 65-year-old female with right-sided facial weakness after dengue fever.
Our patient is a 65-year-old female, without any significant past medical illness presented with a history of generalized body ache followed after 5 days by acute-onset slurring of speech and deviation of the mouth to the left side. Family members also noticed that she was unable to close her right eye. There was no history of diplopia, dysphagia, limb weakness, or paresthesia. There was no history of fever, ear pain, discharge, or parotid enlargement. On presentation, she was conscious, alert and following verbal commands, was stable hemodynamically, and her physical examination was
